Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) patented delivery technology, DehydraTECH™ has positioned the company at the forefront of the thriving global cannabis industry. A recent article discussing this reads: “LXRP’s technology enables improved delivery of bioactive substances via oral ingestion that results in increased absorption without the need for unhealthy practices of inhalational dosing that result in damaging affects to the lungs. The technology also eliminates the need for co-administration with unhealthy sugars or sweeteners in delivery that are commonly used to mask the bitter tastes. With DehydraTECH™, bioactive substance delivery is improved by combining molecules with certain fatty acids and carriers, then dehydrated in order to not only accommodate delivery via taste receptors but also accelerate effects as well as intestinal absorption (with accelerated rate of absorption up to 10 times), providing an improved consumer experience and lower cost per dose.”
Read the full article
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Read More
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Sets its Sights on Booming Global Cannabis Industry
